<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581460</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200747</org_study_id>
    <secondary_id>2020-A01781-38</secondary_id>
    <nct_id>NCT04581460</nct_id>
  </id_info>
  <brief_title>Primitive Immunodeficiency and Pregnancy</brief_title>
  <acronym>PREPI</acronym>
  <official_title>Primitive Immunodeficiency and Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of patients with primary immune deficiency is increasingly codified, however&#xD;
      contraception and pregnancy have not yet extensively studied or codified, and the medical&#xD;
      monitoring and the prevention of infectious complications thus remains at the discretion of&#xD;
      the practitioner.&#xD;
&#xD;
      The aim the research is to study the obstetric features and outcome of patients with primary&#xD;
      immune defects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary immune deficiencies constitute a large group of immune system disorders of genetic&#xD;
      origin which can associate, to varying degrees, an increased susceptibility to infections and&#xD;
      immunopathological manifestations: allergy, inflammation, autoimmunity, lymphoproliferation,&#xD;
      tumors malignant.&#xD;
&#xD;
      Although their prevalence remains underestimated, there has been an increase in the number of&#xD;
      cases diagnosed in the past 10 years. The national average prevalence is 8.6 patients per&#xD;
      100,000 inhabitants and the diagnostic incidence is 400 new cases per year in France. Major&#xD;
      improvement in the management of primary immunodeficiencies have drastically changed patients&#xD;
      outcome. Most patients now reach adulthood and the possibility of carrying out a pregnancy&#xD;
      project, that has already reported for patients suffering from hypogammaglobulinemia or&#xD;
      variable common immune deficiency, is now increasingly reported for other types of inherited&#xD;
      immunodeficiencies. Whereas the management of patients with hereditary immunodeficiencies is&#xD;
      increasingly codified, contraception and pregnancy have not yet been the subject of&#xD;
      recommendations: medical monitoring and the prevention of infectious complications thus&#xD;
      remain at the discretion of the practitioner.&#xD;
&#xD;
      The aim the research is to study the obstetric experiences of patients with a primary immune&#xD;
      deficiency, paying particular attention to infectious complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Infectious events</measure>
    <time_frame>1 year</time_frame>
    <description>Number of infectious events at any time during pregnancy and post-partum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infectious gynecological complications</measure>
    <time_frame>Up to 50 years</time_frame>
    <description>Number of infectious gynecological complications during contraception</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of pregnancy</measure>
    <time_frame>Up to 50 years</time_frame>
    <description>Number of pregnancies during reproductive age period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcomes</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Rate of early or late miscarriage, completed pregnancy, live birth and childbearing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatments</measure>
    <time_frame>9 months</time_frame>
    <description>Number of treatments aiming at preventing infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Screening of infections</measure>
    <time_frame>9 months</time_frame>
    <description>Presence/absence of screening for infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of obstetric complications</measure>
    <time_frame>9 months</time_frame>
    <description>Rate of obstetric complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contraception effectiveness</measure>
    <time_frame>Up to 50 years</time_frame>
    <description>Number of unwanted pregnancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contraception complications</measure>
    <time_frame>Up to 50 years</time_frame>
    <description>Number of non-infectious complications of contraception</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deaths and complications in the neonatal period</measure>
    <time_frame>3 months</time_frame>
    <description>Number of complications during neonatal period, including death</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Primary Immune Deficiency</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients entered in the register of the reference Center for Hereditary Immune Deficits (CEREDIH), hospital Necker-Enfants Malades, Paris, and having reported at least one pregnancy or attempted pregnancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Questionnaire intended for patients on the course of pregnancy and postpartum, the neonatal period and contraceptive modalities.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients with any inherited immune defect included in the CEREDIH national cohort&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult woman with Hereditary Immune Deficits and entered in the reference Center for&#xD;
             Hereditary Immune Deficits (CEREDIH, hospital Necker-Enfants Malades, Paris) register&#xD;
&#xD;
          -  Patient having reported at least one pregnancy or attempted pregnancy&#xD;
&#xD;
          -  Patient not opposing to participation in research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Refusal to participate of the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elise Mallart</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caroline Charlier-Woerther, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nizar Mahlaoui, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elise Mallart</last_name>
    <phone>1 44 49 52 62</phone>
    <phone_ext>+33</phone_ext>
    <email>elise.mallart@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène Morel</last_name>
    <phone>1 44 38 16 53</phone>
    <phone_ext>+33</phone_ext>
    <email>helene.morel@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise Mallart</last_name>
      <phone>1 44 49 52 62</phone>
      <phone_ext>+33</phone_ext>
      <email>elise.mallart@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary immune deficiency</keyword>
  <keyword>Obstetric experiences</keyword>
  <keyword>Infectious complications</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Postpartum</keyword>
  <keyword>Contraception</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

